ADVB revenueFY2026$127.6K
ADVB revenue was $127.6K for fiscal 2026 (ended Jun 30, 2026).
Advanced Biomed Inc. (ADVB) financials
For fiscal 2026 (ended Jun 30, 2026), Advanced Biomed Inc. reported $127.6K of revenue and $6.68M of net income.
- Revenue, FY2026
- $127.6K
- Net income, FY2026
- $6.68M
- Net margin
- 5231.3%
- EPS, diluted, FY2026
- $5.33
- Cash
- $385.5K
- P/E
- 0.49
- P/S
- 25.63
- Market cap
- $3.3M
FY2024FY2026
FY2024FY2025
ADVB revenue and earnings growth
ADVB net incomeQ4 2026$695.0K
ADVB net income was $695.0K in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$701.6K a year earlier. For the full fiscal 2026 it was $6.68M, compared with -$3.26M in fiscal 2025.
ADVB EPSQ4 2026-$0.09
ADVB diluted EPS was -$0.09 in fiscal Q4 2026 (ended Jun 30, 2026). For the full fiscal 2026 it was $5.33, compared with -$3.18 in fiscal 2025.
ADVB free cash flowQ3 2026-$241.0K
ADVB free cash flow was -$241.0K in fiscal Q3 2026 (ended Mar 31, 2026), compared with -$3.41M a year earlier. For the full fiscal 2025 it was -$5.86M, compared with -$2.20M in fiscal 2024.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Revenue | $127.6K | - | - |
| Research and development | - | $909.8K | $880.2K |
| Selling, general and admin | $4.63M | $1.09M | $1.66M |
| Operating income | -$6.23M | -$1.09M | - |
| Pre-tax income | -$6.26M | -$1.09M | -$2.78M |
| Income tax | -$1.2K | - | - |
| Net income | $6.68M | -$3.26M | -$2.78M |
| EPS, basic | $5.33 | -$3.18 | -$2.80 |
| EPS, diluted | $5.33 | -$3.18 | -$2.80 |
| Diluted shares | 1.3M | 1.0M | 1.0M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Cash and equivalents | $385.5K | $31.1K | $2.61M |
| Current assets | $13.75M | $22.38M | $3.05M |
| Total assets | $13.75M | $22.86M | $4.46M |
| Current liabilities | $1.47M | $19.24M | $2.73M |
| Total liabilities | $1.47M | $19.38M | $2.80M |
| Shareholders' equity | $12.28M | $3.48M | $1.66M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Operating cash flow | -$1.95M | -$5.83M | -$2.13M |
| Capital expenditures | - | $31.6K | $74.1K |
| Free cash flow | - | -$5.86M | -$2.20M |
| Investing cash flow | -$2.51M | -$31.6K | -$74.1K |
| Financing cash flow | $1.97M | $5.93M | $1.87M |
| Stock-based compensation | $1.73M | - | - |
| Depreciation and amortization | - | $343.8K | $399.6K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | $243.2K | $186.3K | $236.0K | $309.7K | $220.0K | $212.4K | $181.7K | $209.1K | $313.5K | $188.4K | $169.2K |
| Selling, general and admin | $3.98M | $276.6K | $210.3K | $287.9K | $611.4K | $347.5K | $67.7K | $338.3K | $495.5K | $431.9K | $462.9K | $271.1K |
| Pre-tax income | -$12.52M | -$488.9K | $7.00M | -$386.9K | $675.6K | -$1.20M | -$579.5K | -$265.6K | -$809.4K | -$1.06M | -$145.3K | -$771.3K |
| Net income | $695.0K | -$488.9K | $6.86M | -$386.9K | -$701.6K | -$1.38M | -$907.9K | -$265.6K | -$809.4K | -$1.06M | -$145.3K | -$771.3K |
| EPS, basic | -$0.09 | -$0.38 | $6.20 | -$0.40 | -$0.63 | -$1.35 | -$1.00 | -$0.20 | - | -$1.00 | -$0.20 | - |
| EPS, diluted | -$0.09 | -$0.38 | $6.20 | -$0.40 | -$0.63 | -$1.35 | -$1.00 | -$0.20 | - | -$1.00 | -$0.20 | - |
| Diluted shares | - | 1.3M | 1.1M | 1.1M | - | 1.0M | 1.0M | 1.0M | - | 1.0M | 1.0M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $385.5K | $2.60M | $2.60M | $2.66M | $31.1K | $3.18M | $2.65M | $2.65M | $2.61M | $2.66M | $2.78M | - |
| Current assets | $13.75M | $10.53M | $10.73M | $5.84M | $22.38M | $7.73M | $3.14M | - | $3.05M | - | - | - |
| Total assets | $13.75M | $10.65M | $10.85M | $6.24M | $22.86M | $8.29M | $4.50M | - | $4.46M | - | - | - |
| Current liabilities | $1.47M | $1.43M | $1.25M | $3.04M | $19.24M | $4.11M | $3.83M | - | $2.73M | - | - | - |
| Total liabilities | $1.47M | $1.44M | $1.37M | $3.24M | $19.38M | $4.16M | $3.89M | - | $2.80M | - | - | - |
| Shareholders' equity | $12.28M | $9.21M | $9.48M | $3.00M | $3.48M | $4.13M | $619.0K | $1.09M | $1.66M | -$497.8K | $196.8K | - |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$583.3K | -$239.8K | -$513.6K | -$610.3K | -$1.54M | -$3.41M | -$841.8K | -$29.7K | -$475.8K | -$1.07M | - | - |
| Capital expenditures | - | $1.3K | $12.9K | $1.8K | $20.1K | $2.2K | -$10.7K | $20.0K | $53.3K | -$26.7K | - | - |
| Free cash flow | - | -$241.0K | -$526.5K | -$612.1K | -$1.56M | -$3.41M | -$852.5K | -$49.7K | -$529.1K | -$1.09M | - | - |
| Investing cash flow | -$2.49M | -$1.3K | -$12.9K | -$1.8K | -$20.1K | -$2.2K | $10.7K | -$20.0K | -$53.3K | $26.7K | - | - |
| Financing cash flow | $936.8K | $268.3K | $315.5K | $447.5K | -$765.5K | $5.90M | $408.3K | $392.5K | $323.5K | $562.2K | - | - |
| Depreciation and amortization | - | $9.3K | -$12.9K | $48.0K | $275.9K | $22.5K | -$56.8K | $102.2K | $153.9K | $83.0K | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.33 | 7.38 | 8.56 | 1.92 | 1.16 | 1.88 | 0.82 | - | 1.12 | - | - | - |
Source: XBRL data Advanced Biomed Inc. files with the SEC, latest filing dated Oct 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported May 15, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ADVB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ADVB | $127.6K | - | $6.68M | 5231.3% | $3.3M |
| UNH | $449.66B | +3.3% | $15.88B | 3.5% | $353.17B |
| ELV | $201.83B | +3.6% | $5.13B | 2.5% | $91.96B |
| CI | $286.32B | +6.8% | $5.99B | 2.1% | $77.58B |
| HUM | $154.19B | +22.0% | $1.25B | 0.8% | $52.08B |
| NTRA | $2.91B | +37.4% | -$164.71M | -5.7% | $44.78B |
| CNC | $203.90B | +9.7% | $1.46B | 0.7% | $34.53B |
| ILMN | $4.54B | +5.8% | $895.00M | 19.7% | $32.22B |
| LH | $14.59B | +6.0% | $1.00B | 6.9% | $29.77B |
ADVB FAQ
6 questionsWhat is ADVB revenue?
Advanced Biomed Inc. (ADVB) reported $127.6K of revenue for fiscal 2026 (ended Jun 30, 2026).Is ADVB profitable?
Yes. Advanced Biomed Inc. earned $6.68M in net income for fiscal 2026 (ended Jun 30, 2026), a net margin of 5231.3%.How much cash and debt does ADVB have?
Advanced Biomed Inc. reported $385.5K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ADVB earnings per share?
Diluted earnings per share were $5.33 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did ADVB last report financial results?
The latest statements here come from Advanced Biomed Inc.'s 10-K filed on Oct 13, 2026, covering the period ended Jun 30, 2026.Where does this ADVB financial data come from?
Quantisnow builds these statements from the structured XBRL data Advanced Biomed Inc. files with the SEC. It is provided for information only and is not investment advice.